title: Analysis of C-reactive protein levels and febrile tendency after joint surgery in rheumatoid arthritis patients treated with a perioperative 4-week interruption of tocilizumab.
authors.affiliation: Department of Orthopaedic Surgery, Institute of Rheumatology, Tokyo Women's Medical University, 10-22 Kawada, Shinjuku, Tokyo, 162-0054, Japan.
authors.forename: Ryo
authors.initials: R
authors.lastname: Hiroshima
authors.forename: Kosei
authors.initials: K
authors.lastname: Kawakami
authors.forename: Takuji
authors.initials: T
authors.lastname: Iwamoto
authors.forename: Asami
authors.initials: A
authors.lastname: Tokita
authors.forename: Koichiro
authors.initials: K
authors.lastname: Yano
authors.forename: Yu
authors.initials: Y
authors.lastname: Sakuma
authors.forename: Katsunori
authors.initials: K
authors.lastname: Ikari
authors.forename: Shigeki
authors.initials: S
authors.lastname: Momohara
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000378:metabolism / Q000601:surgery; D019643:Arthroplasty, Replacement / Q000009:adverse effects*; D002097:C-Reactive Protein / Q000378:metabolism*; D005260:Female; D005334:Fever / Q000209:etiology / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D012189:Retrospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D028761:Withholding Treatment
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; C502936:tocilizumab